Inclusion Criteria:
1. Aged 18 to 65 years (inclusive) at the time of informed consent.
2. In good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening and/or before the first administration of IMP.
3. Body Mass Index (BMI) between ≥ 18.0 and ≤ 34.9 kg/m2 and weight ≥ 50 kg.
4. Nonsmoker and must not have used any tobacco or nicotine-containing products within 2 months prior to Screening.
5. Clinical laboratory values within normal range at Screening and Day -1, as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee.
6. Estimated glomerular filtration rate (eGFR) \> 80 mL/min/1.73 m² at Screening and Day-1.
7. Not pregnant or breastfeeding, or willing to cease breastfeeding. Woman of childbearing potential (WOCBP) (agrees to use an acceptable highly effective contraception method from the start of Screening until 90 days after the last dose of IMP or who are abstinent from heterosexual intercourse are not required to use contraception when this is their preferred and usual lifestyle. Male partners of WOCBP must use condom from the start of Screening until 90 days after the last dose of IMP. WOCBP must have a negative pregnancy test at Screening (serum) and Day -1 (urine). Females must agree to not donate ova from the first dose of IMP until at least 90 days after the last dose of IMP or 5 half-lives, whichever is longer.
8. Women not of childbearing potential (WONCBP) must be postmenopausal for ≥ 12 months (postmenopausal status is to be confirmed through testing of follicle-stimulating hormone \[FSH\] levels ≥ 40 IU/L at Screening for amenorrhoeic female participants). Women on hormone replacement therapy (HRT) will need to be on stable regimen for at least 3 months before Screening.
9. Males must be surgically sterile (\> 30 days since vasectomy \[documented evidence\] with no viable sperm before first administration of IMP), or, if engaged in sexual relations with a WOCBP, they must use a condom and either his partner must be surgically sterile (eg, tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy), or an acceptable, highly effective contraceptive method must be used from Screening until 90 days after the last dose of the IMP. Males with same-sex partners (abstinent from penile-vaginal intercourse) or abstinent from heterosexual intercourse are not required to use contraception when this is their preferred and usual lifestyle. Males with WONCBP partners where that partner is the sole sexual partner are not required to use contraception. Males must not donate sperm from the first dose of IMP until at least 90 days after the last dose of IMP or 5 half-lives, whichever is longer.
10. Informed consent form signed before initiation of any study procedures
11. Willing and able to comply with all protocol procedures and assessments required for the study.
12. Has adequate venous access for blood collection.
Exclusion Criteria:
1. Underlying physical or psychological medical condition that, in the opinion of the PI or designee, would make the participant unlikely to comply with the protocol or complete the study per protocol.
2. Blood, plasma or platelets donation or had significant blood loss (\> 500 mL) within 30 days prior to the first administration of IMP.
3. Fever (tympanic temperature \> 37.7°C) or symptomatic viral or bacterial infection within 1 week prior to Screening.
4. Dysphagia that would limit ability to swallow IMP.
5. Positive test for hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), human immunodeficiency virus (HIV) types 1 and 2 antibody at Screening.
6. Vaccination with a live vaccine within 4 weeks prior to the first administration of IMP, during the study and 2 weeks post last administration of IMP. Vaccination with non-live vaccinations is not allowed for the duration of study.
7. History of life-threatening infection (eg, meningitis) that in the opinion of PI may increase the risk to the participant or interfere with study assessments.
8. History of malignancy, except for non-melanoma skin cancer, excised more than 2 years ago and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to Screening.
9. History of severe allergic or anaphylactic reactions, or sensitivity to the IMP or its constituents.
10. Cardiovascular disease including heart failure with reduced left ventricular ejection fraction, atrial fibrillation requiring anticoagulation, or any other cardiovascular illness that, in the opinion of the PI, warrants exclusion from the study.
11. History of hospitalisation or major surgery within 6 months prior to Screening.
12. Infections requiring parenteral antibiotics within 6 months prior to Screening.
13. Abnormal mean triplicate ECG findings at Screening, and Day -1 that are considered by the PI or designee to be clinically significant
14. Unstable vital sign(s) or the following values seen at Screening, Day -1 or on Day 1 following 5 minutes of resting in the supine position
15. Positive toxicology Screening panel (urine test including qualitative identification of methamphetamines, opiates, cocaine, cannabinoid \[THC\], phencyclidine, benzodiazepines, barbiturates, methadone, tricyclic antidepressants, amphetamines.), positive alcohol breath test at Screening or Day -1; positive cotinine screen test at Day -1.
16. History of substance abuse or dependency or history of recreational intravenous (IV) drug use over the last 5 years (by self-declaration).
17. Regular alcohol consumption defined as \> 10 standard drinks per week (where 1 standard drink = 360 mL of beer, 45 mL of 40% spirit or a 150 mL glass of wine) or \> 4 standard drinks on any single day.
18. Unwilling to abstain from alcohol and nicotine-containing products (eg, cigar, cigarettes, vapes) from 72 hours prior to admission to the study site until discharge from study site and from 24 hours prior to any follow-up visits.
19. Use of any investigational medical device or investigational drug within 30 days or 5 half lives of the investigational drug (whichever is longer) prior to the Screening.
20. Use of any prescription drugs (other than regular contraceptives like hormonal contraception; oral contraceptive pills, long-acting implantable hormones, injectable hormones, a vaginal ring, or an intrauterine device \[IUD\]), over-the-counter medication, herbal remedies, supplements or vitamins within 14 days prior to the first administration of IMP or anticipated use during the course of the study without prior approval of the PI and MM. Simple analgesia (paracetamol, nonsteroidal anti-inflammatory drug \[NSAID\]) may be permitted at the discretion of the PI.
21. Use of any NAD modulating supplements
22. Anything that the PI considers would jeopardise the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.